A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
暂无分享,去创建一个
[1] J. Nutt,et al. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.
[2] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[3] W Tatton,et al. The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo , 2001, Annals of the New York Academy of Sciences.
[4] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[5] Y. Akao,et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells , 2002, Neuroscience Letters.
[6] P Leber,et al. Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.
[7] Y. Akao,et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. , 2002, Neurotoxicology and teratology.
[8] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[9] E. Shohami,et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. , 1999, European journal of pharmacology.
[10] A. Bazzan,et al. [Amantadine in the treatment of Parkinson's disease]. , 1970, Il Fracastoro.
[11] P. Lazarovici,et al. Rasagiline, a monoamine oxidase‐B inhibitor, protects NGF‐differentiated PC12 cells against oxygen‐glucose deprivation , 1999, Journal of neuroscience research.
[12] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[13] Y. Akao,et al. Mitochondrial permeability transition mediates apoptosis induced by N‐methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl‐2 and rasagiline, N‐propargyl‐1(R)‐aminoindan , 2002, Journal of neurochemistry.
[14] M. Carrillo,et al. Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline , 2000, Mechanisms of Ageing and Development.
[15] R Kieburtz,et al. Effect of lazabemide on the progression of disability in early Parkinson's disease , 1996, Annals of neurology.
[16] M. Youdim,et al. TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B , 1981, British journal of pharmacology.
[17] R. Duvoisin,et al. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. , 1985, European journal of pharmacology.